Literature DB >> 19597475

PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers.

P Klanrit1, P Taebunpakul, M B Flinterman, E W Odell, M A Riaz, G Melino, P Salomoni, J S Mymryk, J Gäken, F Farzaneh, M Tavassoli.   

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase is commonly overexpressed in human cancers; however, the cellular mechanisms regulating EGFR expression remain unclear. p53, p63 and p73 are transcription factors regulating many cellular targets involved in controlling the cell cycle and apoptosis. p53 activates EGFR expression, whereas TAp63 represses EGFR transcription. The involvement of p73 in the regulation of EGFR has not been reported. Here, a strong correlation between EGFR overexpression and increased levels of the oncogenic DeltaNp73 isoform in head and neck squamous cell carcinoma (HNSCC) cell lines was observed. Ectopic expression of TAp73, particularly TAp73beta, resulted in suppression of the EGFR promoter, significant downregulation of EGFR protein and efficient induction of cell death in all six EGFR-overexpressing HNSCC cell lines. EGFR overexpression from a heterologous LTR promoter protected lung cancer cells from TAp73beta-induced EGFR suppression and apoptosis. Expression of TAp73beta efficiently induced promyelocytic leukaemia (PML) protein expression and PML knockdown by shRNA attenuated the downregulation of EGFR and induction of apoptosis by p73 in HNSCC cells. Furthermore, PML was found to be important for E1A-induced suppression of EGFR and subsequent killing of HNSCC cells. Our data therefore suggest a novel pathway involving PML and p73 in the regulation of EGFR expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19597475      PMCID: PMC2882231          DOI: 10.1038/onc.2009.191

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  51 in total

Review 1.  The role of PML in tumor suppression.

Authors:  Paolo Salomoni; Pier Paolo Pandolfi
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

Review 2.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.

Authors:  N Prenzel; O M Fischer; S Streit; S Hart; A Ullrich
Journal:  Endocr Relat Cancer       Date:  2001-03       Impact factor: 5.678

3.  Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue.

Authors:  K Specht; T Richter; U Müller; A Walch; M Werner; H Höfler
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  E1A-mediated suppression of EGFR expression and induction of apoptosis in head and neck squamous carcinoma cell lines.

Authors:  Marcella Flinterman; Joop Gäken; Farzin Farzaneh; Mahvash Tavassoli
Journal:  Oncogene       Date:  2003-04-03       Impact factor: 9.867

5.  The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases.

Authors:  W S Wu; S Vallian; E Seto; W M Yang; D Edmondson; S Roth; K S Chang
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

6.  p53 Homologue p63 represses epidermal growth factor receptor expression.

Authors:  H Nishi; M Senoo; K H Nishi; B Murphy; T Rikiyama; Y Matsumura; S Habu; A C Johnson
Journal:  J Biol Chem       Date:  2001-09-06       Impact factor: 5.157

Review 7.  p73: Friend or foe in tumorigenesis.

Authors:  Gerry Melino; Vincenzo De Laurenzi; Karen H Vousden
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

8.  c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route.

Authors:  A A de Melker; G van der Horst; J Calafat; H Jansen; J Borst
Journal:  J Cell Sci       Date:  2001-06       Impact factor: 5.285

9.  Deconstructing PML-induced premature senescence.

Authors:  Oliver Bischof; Olivier Kirsh; Mark Pearson; Koji Itahana; Pier Giuseppe Pelicci; Anne Dejean
Journal:  EMBO J       Date:  2002-07-01       Impact factor: 14.012

10.  DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.

Authors:  Alex I Zaika; Neda Slade; Susan H Erster; Christine Sansome; Troy W Joseph; Michael Pearl; Eva Chalas; Ute M Moll
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

View more
  4 in total

Review 1.  A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression.

Authors:  D Engelmann; C Meier; V Alla; B M Pützer
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

Review 2.  Development of head and neck pathology in Europe.

Authors:  Henrik Hellquist; Abbas Agaimy; Göran Stenman; Alessandro Franchi; Alfons Nadal; Alena Skalova; Ilmo Leivo; Nina Zidar; Roderick H W Simpson; Pieter J Slootweg; Juan C Hernandez-Prera; Alfio Ferlito
Journal:  Virchows Arch       Date:  2022-01-14       Impact factor: 4.064

Review 3.  Role of the promyelocytic leukaemia protein in cell death regulation.

Authors:  P Salomoni; M Dvorkina; D Michod
Journal:  Cell Death Dis       Date:  2012-01-12       Impact factor: 8.469

Review 4.  Clinical update on head and neck cancer: molecular biology and ongoing challenges.

Authors:  Elham Alsahafi; Katheryn Begg; Ivano Amelio; Nina Raulf; Philippe Lucarelli; Thomas Sauter; Mahvash Tavassoli
Journal:  Cell Death Dis       Date:  2019-07-15       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.